Clinical Trial Update: Study to Evaluate the Safety and Effectiveness of USL255 in Patients With Refractory Partial-onset Seizures [Phase 3]

View source ↗

Summary

Phase 3 study evaluating USL255 for refractory partial-onset seizures has completed. Results were posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy
• Partial-onset Seizures

Drugs mentioned

• USL255 (topiramate)

Snippet

Sponsor: Upsher-Smith Laboratories | Conditions: Epilepsy | Phase 3 | Status: COMPLETED | Results posted: 2014-05-07